TABLE 1 Maximum Recommended Daily Doses for Nonsedating Antihistamines in Adults (Monotherapy and Combination Therapy)
5 mg once daily Levocetirizine (Xyzal®, generics) tablet -5 mg Levocetirizine (Xyzal®, generics) oral solution -2.5 mg/5 ml 5 mg once daily in evening ** Loratadine (Claritin®, Alavert®, generics) tablets -10 mg ** Loratadine chewable (Claritin Children's®) tablets -5 mg 
Pediatrics
Oral nonsedating antihistamines are FDA-approved for use in pediatric patients for allergic rhinitis and chronic urticaria. Cetirizine is FDA-approved for use in children 2 years and older with urticaria and allergic rhinitis, levocetirizine and desloratadine are FDA-approved for use in children 6 months of age and older with chronic idiopathic urticaria and perennial allergic rhinitis and 2 years of age and older for seasonal allergic rhinitis, loratadine is FDA-approved for use in children 2 years and older for allergic rhinitis, and fexofenadine is FDA-approved for use in children 6 months and older for chronic idiopathic urticaria and children 2 years and older for seasonal allergic rhinitis. Safety and efficacy of nonsedating antihistamine/decongestant combination products have not been established in children less than 12 years of age. Nasal nonsedating antihistamines are FDA-approved for use in children 5 years and older for seasonal allergic rhinitis treatment (Astelin® only), children 6 years and older for seasonal allergic rhinitis therapy (olopatadine only), and pediatric patients 12 years and older in managing perennial allergic rhinitis (Astepro® only), seasonal allergic rhinitis, and vasomotor rhinitis (Astelin® only). Maximum recommended pediatric dosages for available nonsedating antihistamines are summarized in Table 2 . Dosages identified in Texas Medicaid patients exceeding these recommendations will be reviewed.
Duration of Therapy
There is no basis for limiting the duration of treatment for nonsedating antihistamines as patients may suffer from symptoms of allergic rhinitis or other chronic allergic conditions continually.
3.* Duplicative Therapy
The concurrent use of two or more nonsedating antihistamines is not recommended. Additional therapeutic benefit is not experienced when several antihistamines are administered in combination. Patient profiles containing concurrent prescriptions for multiple nonsedating antihistamines will be reviewed.
4.* Drug-Drug Interactions
Patient profiles will be assessed to identify those drug regimens which may result in clinically significant drug-drug interactions.
Drug-drug interactions considered clinically significant for nonsedating antihistamines are summarized in Table 3 . Only those drug-drug interactions classified as clinical significance level 1/ contraindicated or those considered life-threatening which have not yet been classified will be reviewed: 
